Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis
, , , , , oraz
19 cze 2024
O artykule
Data publikacji: 19 cze 2024
Zakres stron: 90 - 96
DOI: https://doi.org/10.2478/pneum-2024-0014
Słowa kluczowe
© 2023 Victoria Țau et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Țau, Victoria
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Antal, Andreea Zabară
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Doctoral School, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”Iași, Romania
Antohi, Paula Vasilache
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Stoian, Ioana Adelina
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Doctoral School, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”Iași, Romania
Pintilie, Adriana Loredana
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Trofor, Antigona Carmen
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Pulmonary Department, Faculty of General Medicine, University of Medicine and Pharmacy “Grigore T. Popa,”Iași, Romania
Crișan-Dabija, Radu Adrian
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Pulmonary Department, Faculty of General Medicine, University of Medicine and Pharmacy “Grigore T. Popa,”Iași, Romania